Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-ILT4/anti-PD-L1 bispecific antibody SPX-303

A bispecific antibody directed against both the inhibitory immune checkpoint receptor immunoglobulin-like transcript 4 (ILT4; leukocyte immunoglobulin-like receptor subfamily B member 2; LILRB2; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory, immunostimulatory and antineoplastic activities. Upon administration, anti-ILT4/anti-PD-L1 bispecific antibody SPX-303 targets and binds to both ILT4 and PD-L1. The binding of SPX-303 to ILT4 prevents activation by its ligands, including the major histocompatibility complex class I (MHC I) molecules human leukocyte antigen (HLA)-A, HLA-B, HLA-C and HLA-G, and inhibits ILT4-mediated signaling. This abrogates the immunosuppressive activities of ILT4 in the tumor microenvironment (TME), activates the expression of pro-inflammatory cytokines, including GM-CSF and tumor necrosis factor alpha (TNFalpha), and enhances a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response. The binding of SPX-303 to PD-L1 prevents the binding to its receptor, programmed cell death protein 1 (PD-1, CD279), inhibits the PD-1/PD-L1-mediated signaling, and inhibits the PD-1/PD-L1-mediated downregulation of T-cell activation and proliferation. This restores and enhances a CTL-mediated immune response against tumor cells. PD-L1, which is overexpressed in many human cancer cell types, plays an important role in the downregulation of the immune system and tumor evasion from host immunity. ILT4, a transmembrane protein and inhibitory member of the immunoglobulin-like transcript (ILT) family of proteins, is expressed primarily by myeloid cells, including monocytes, macrophages, dendritic cells (DCs) and granulocytes, and certain tumor cells; it also plays a role in tumor evasion.
Synonym:anti-ILT4/PD-L1 bispecific antibody SPX-303
anti-LILRB2/anti-PD-L1 bispecific antibody SPX-303
anti-LILRB2/PD-L1 bispecific antibody SPX-303
anti-PD-L1/anti-LILRB2 bispecific antibody SPX-303
LILRB2 x PD-L1 bispecific antibody SPX-303
Code name:SPX 303
SPX-303
SPX303
Search NCI's Drug Dictionary